TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1691403

Group type: EXPERIMENTAL
Intervention: Quinapril (10-40 mg/day, up to 80 mg/day)
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Quinapril (once daily)
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Quinapril (10-40 mg/day)
Number of subjects: 2187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2187

Group type: COMPARATOR
Intervention: Captopril (two or three times daily)
Number of subjects: 2187

Group type: COMPARATOR
Intervention: Enalapril (once daily)
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Diuretics (optional for nonresponders)
Number of subjects: 2187
Study: 6271384

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy‐irradiation (CT‐RT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Three‐week course of concurrent CT‐RT
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Concurrent therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sequential CT‐RT
Number of subjects: 71
Study: 31655841

Group type: EXPERIMENTAL
Intervention: Laser therapy (K Laser Cube 3)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Sham therapy (placebo)
Number of subjects: 85
Study: 28453740

Group type: EXPERIMENTAL
Intervention: Moderate exercise at 65% of maximal aerobic capacity for 30 minutes
Number of subjects: 23
Study: 26319423

Group type: EXPERIMENTAL
Intervention: Vit B12 1000 microgram/day, B6 3 mg/day & folic acid 5 mg/day
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Control arm (existing interventions)
Number of subjects: 12000
Study: 23305251

Group type: EXPERIMENTAL
Intervention: Strategy involving physician accountability, including distribution of patient lists compatible with discharge and physician length of stay profiles, followed by audits managed by ward physicians.
Number of subjects: 3498

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 3498

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups.
Number of subjects: 3498
Study: 21563042

Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine topical patch 1.3%
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 418
Study: 18474882

Group type: EXPERIMENTAL
Intervention: Intervention materials received by physicians
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Decreased antibiotic prescribing
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Knowledge, attitudes, or behaviors favoring judicious antibiotic use
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Concern about antibiotic resistance
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Room to reduce prescribing
Number of subjects: 168
Study: 16612452

Group type: EXPERIMENTAL
Intervention: Intermittent pressure (Müller Resuscitator Group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP Group)
Number of subjects: 40
Study: 12709086

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study: 10844862

Group type: EXPERIMENTAL
Intervention: Agfa HDR film
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fuji UMMA film
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Agfa HDR film and Fuji UMMA film
Number of subjects: 54
Study: 8804327

Group type: EXPERIMENTAL
Intervention: Orally administered iron for 6 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1511045

Group type: EXPERIMENTAL
Intervention: Clonidine (CLO)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Enalapril (EN)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Washout period
Number of subjects: 9
Study: 6229429

Group type: EXPERIMENTAL
Intervention: Isotretinoin 1.0 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.5 mg/kg
Number of subjects: 58
Study: 29767425

Group type: EXPERIMENTAL
Intervention: Chewing 15 times per bite
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Chewing 50 times per bite
Number of subjects: 41
Study: 29288190

Group type: COMPARATOR
Intervention: Standard TME surgery (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organ-saving treatment using long-course concurrent chemoradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organ-saving treatment using short-course radiotherapy
Number of subjects: 0
Study: 27099954

Group type: EXPERIMENTAL
Intervention: Rice group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Steamed buns group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 22
Study: 24709495

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4 μg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.8 μg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 90
Study: 22371640

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d) with Pegylated α-interferon-2a plus oral ribavirin 800 mg/d for 24 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group received identical therapy without vitamin D
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline serum vitamin D levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BMI (< 30 or > 30)
Number of subjects: 50
Study: 19756664

Group type: EXPERIMENTAL
Intervention: Combination therapy of etanercept and methotrexate (MTX)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 686
Study: 18441623

Group type: EXPERIMENTAL
Intervention: Hair-washing 72 hours postoperatively (n = 48)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No hair washing until suture or clip removal (n = 52)
Number of subjects: 100
Study: 15449975

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg/day for 6 weeks, then either maintained or increased to 8 mg/day based on BP response.
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day for 6 weeks (group II).
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Perindopril monotherapy.
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day for group II patients.
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Perindopril monotherapy in hypertensive diabetic patients.
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Perindopril treatment in very elderly patients (>75 years).
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Perindopril treatment.
Number of subjects: 3010
Study: 11368989

Group type: EXPERIMENTAL
Intervention: Post-placental insertion of a copper T380A intrauterine device (IUD)
Number of subjects: 302

Group type: COMPARATOR
Intervention: No IUD insertion (control group)
Number of subjects: 302
Study: 9045337

Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m2 plus carboplatin (AUC 6)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin regimen
Number of subjects: 16
Study: 8435379

Group type: EXPERIMENTAL
Intervention: Torasemide 100 mg intravenous dose in patients with moderate renal insufficiency
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Torasemide 200 mg intravenous dose in patients with severe renal insufficiency
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Torasemide (various doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 24
Study: 3677786

Group type: EXPERIMENTAL
Intervention: Benfluorex (450 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 28501343

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Low-fat diet with exercise
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet with exercise
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Decreased sodium intake
Number of subjects: 278
Study: 27557865

Group type: EXPERIMENTAL
Intervention: 67 % sodium bicarbonate-containing dentifrice
Number of subjects: 150

Group type: COMPARATOR
Intervention: Commercially available NaF silica dentifrice without NaHCO3
Number of subjects: 150
Study: 24497599

Group type: EXPERIMENTAL
Intervention: Polyhexanide solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional care with saline serum and povidone-iodine
Number of subjects: 60
Study: 23582589

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: MR-proANP
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 1456
Study: 20081225

Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Ciclosporin vs Azathioprine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Ciclosporin and Azathioprine
Number of subjects: 89
Study: 18374544

Group type: EXPERIMENTAL
Intervention: Aripiprazole (ARI) 10-30 mg/day
Number of subjects: 555

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 555
Study: 16651506

Group type: EXPERIMENTAL
Intervention: Psychotic symptoms (positive and negative)
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Co-occurring substance abuse and interpersonal/social factors
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Psychotic and depressive symptoms, childhood conduct problems, and victimization
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Any violence
Number of subjects: 1410
Study: 12814905

Group type: EXPERIMENTAL
Intervention: Ondansetron treatment (1, 4, and 16 micro g/kg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10508811

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg once daily for 2 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 7484516

Group type: EXPERIMENTAL
Intervention: Flutamide with orchiectomy
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Flutamide with LHRH analogues
Number of subjects: 546

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 546
Study: 1851683

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Untreated (control)
Number of subjects: 9
Study: 7177292

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (Normal subjects)
Number of subjects: 22
Study: 29553345

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27286961

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-carboxymethylcellulose treatment (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 60
Study: 24984823

Group type: EXPERIMENTAL
Intervention: Magnesium supplements (8.1mmol of magnesium-pidolate, administered twice a day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Magnesium supplements
Number of subjects: 14
Study: 22187144

Group type: EXPERIMENTAL
Intervention: Philos system (Philos, proximal humeral internal locking system, Synthes GmbH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Königsee plate system (Königsee Implantate GmbH)
Number of subjects: 60
Study: 20424828

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58
Study: 18561516

Group type: EXPERIMENTAL
Intervention: Guidance on lifestyle modifications (single visit)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidance on lifestyle modifications (multiple visits every two months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 15864643

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DX) 0.25 mg/kg at 12 h intervals for four doses
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DX) early prolonged (>96 h)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DX) early short (<96 h)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 109
Study: 11815760

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (1 mg/kg, 1 dose)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 10087861

Group type: EXPERIMENTAL
Intervention: Preexposure of the same problem in the same notation (number words and dot configurations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preexposure of the same problem in Arabic digit, number word, and dot notation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task performed on preexposure trials (addition or multiplication) matching the task on repetition trials (addition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Notation matching across repetitions (number words and dot configurations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Notation matching across repetitions (Arabic digits)
Number of subjects: 0
Study: 7752010

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 99
Study: 2311727

Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 33

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 33
Study: 6161451

Group type: EXPERIMENTAL
Intervention: Solcoseryl gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluorescence microscopy
Number of subjects: 60
Study: 6353619

Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray (200 micrograms, twice daily for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flunisolide nasal spray and Placebo
Number of subjects: 20
Study: 30246883

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (weight reduction diet + bolus weekly dose of 50,000 IU vitamin D)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (weight reduction diet + edible paraffin weekly)
Number of subjects: 44
Study: 28823697

Group type: EXPERIMENTAL
Intervention: Gelfoam patch‐treated group
Number of subjects: 114

Group type: COMPARATOR
Intervention: Spontaneous healing group
Number of subjects: 114
Study: 26806596

Group type: EXPERIMENTAL
Intervention: Hands and knees position for at least 10 minutes
Number of subjects: 439

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 439
Study: 24323030

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 551

Group type: COMPARATOR
Intervention: Aprepitant
Number of subjects: 551
Study: 22579722

Group type: EXPERIMENTAL
Intervention: Folic acid tablet (∼1,000 μg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Multivitamin softgel capsule (∼1,000 μg)
Number of subjects: 16
Study: 20805454

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem-cell transplantation (HSCT) from matched related donors (MRD) and matched unrelated donors (MUD)
Number of subjects: 844

Group type: COMPARATOR
Intervention: No HSCT
Number of subjects: 844
Study: 18073546

Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-assisted internal jugular venous catheterization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound-guided skin-marking method
Number of subjects: 60
Study: 16163525

Group type: EXPERIMENTAL
Intervention: Alcohol (0.65 g/kg) after prior task experience with visual degradation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Visual degradation after prior task experience under active alcohol (0.65 g/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (inactive) after prior task experience with visual degradation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group repeating each active treatment
Number of subjects: 42
Study: 12230903

Group type: EXPERIMENTAL
Intervention: Q Link Ally (QL) added to active mobile phone exposure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Active mobile phone exposure
Number of subjects: 24
Study: 10545590

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (2 x 10^10 colony-forming units in capsules given twice daily during antimicrobial treatment)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo (indistinguishable in appearance and taste)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Lactobacillus GG and Placebo
Number of subjects: 119
Study: 7570411

Group type: EXPERIMENTAL
Intervention: Amoxicillin (500 mg three times daily)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (960 mg twice daily)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Amoxicillin, Cotrimoxazole, or Placebo with oral corticosteroids
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Amoxicillin, Cotrimoxazole, or Placebo
Number of subjects: 195
Study: 2303333

Group type: EXPERIMENTAL
Intervention: Blue/yellow sensitivity
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional perimetric sensitivity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Blue/yellow color‐contrast perimetry
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional (luminance‐increment) perimetry
Number of subjects: 30
Study: 6985560

Group type: EXPERIMENTAL
Intervention: bezafibrate (3 x 200 mg/d for 8 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: clofibrate (3 x 500 mg/d for 8 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: bezafibrate and clofibrate
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 22
Study: 31995662

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 30103755

Group type: EXPERIMENTAL
Intervention: Long-lasting insecticidal nets (LLINs) usage
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Malaria parasite prevalence
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Socio-economic status impact on parasitaemia
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Gender differences in parasitaemia
Number of subjects: 2000
Study: 28594602

Group type: EXPERIMENTAL
Intervention: TAU plus a nine-hour AS-focused intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 41
Study: 24326780

Group type: EXPERIMENTAL
Intervention: Experimental knee effusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 0
Study: 24030946

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 56

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 56
Study: 21173180

Group type: EXPERIMENTAL
Intervention: Miconazole oral gel (85 mg thrice daily)
Number of subjects: 12
Study: 19025522

Group type: EXPERIMENTAL
Intervention: 3 ml (18 mg) hypobaric 0.6% lidocaine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 4 ml (24 mg) hypobaric 0.6% lidocaine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 5 ml (30 mg) hypobaric 0.6% lidocaine
Number of subjects: 150
Study: 16987361

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided perivascular approach (Group US)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Transarterial technique (Group TA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 14550362

Group type: COMPARATOR
Intervention: General anaesthetic
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Local anaesthetic
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Local anaesthetic in clinic setting
Number of subjects: 127
Study: 11037040

Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9483755

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 24

Group type: COMPARATOR
Intervention: No oral contraceptives (control group)
Number of subjects: 24
Study: 8318401

Group type: EXPERIMENTAL
Intervention: Hypothetical therapy with 50% enhancement of median survival time (to 5.1 years)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Hypothetical therapy with 50% enhancement of cured fraction (to 40.5%)
Number of subjects: 500
Study: 3488140

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29542816

Group type: EXPERIMENTAL
Intervention: Positive attention bias modification training (ABMT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition (50% positive stimuli)
Number of subjects: 60
Study: 27707440

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4,000 IU daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 26277173

Group type: EXPERIMENTAL
Intervention: Underweight children
Number of subjects: 60
Study: 23766519

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol (D₃) 600,000 IU
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol (D₂) 600,000 IU
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intramuscular cholecalciferol (D₃) 600,000 IU
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intramuscular ergocalciferol (D₂) 600,000 IU
Number of subjects: 24
Study: 21112864

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18405151

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment (routine western medicine combined with acupuncture, moxibustion, and enema of Chinese drugs)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Western medicine group (routine western methods including dehydration, brain-protection, anti-platelet agglutination, improving circulation, and expectant treatment)
Number of subjects: 96
Study: 17027422

Group type: EXPERIMENTAL
Intervention: Trial Protocol Tool (developed in English and Spanish)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial Protocol Tool
Number of subjects: 0